Anti-peptide antibodies that cross react with protective antigen of
View Patent ↗The present invention provides a purified peptide comprising at least one of the sequences LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a vaccine, a method to protect or treat an animal from anthrax toxin, a method of making a vaccine and the use of the peptide. The present invention also provides a monoclonal antibody that specifically binds to a peptide sequence comprising at least one of the following peptide sequences: LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a method to protect or treat an animal from anthrax toxin, a method of making a vaccine, a pharmaceutical composition, a method of making a pharmaceutical composition, and the use of the monoclonal antibody.
1. A purified peptide consisting of the amino acid sequence LKQKSSNSRKKRSTS (SEQ ID NO:1) or the amino acid sequence VKNKRTFLSPWISNI (SEQ ID NO:2).
2. The purified peptide of claim 1 consisting of the sequence LKQKSSNSRKKRSTS (SEQ ID NO:1).
3. The purified peptide of claim 1 consisting of the sequence VKNKRTFLSPWISNI (SEQ ID NO:2).
4. An anthrax vaccine comprising a multiple antigenic peptide comprising a lysine backbone and multiple peptide epitopes attached to the backbone, wherein the multiple peptide epitopes comprise multiple copies of one or both of the amino acid sequences of the peptide of claim 1 .
5. The vaccine of claim 4 wherein the multiple antigenic peptide comprises the sequence LKQKSSNSRKKRSTS (SEQ ID NO:1).
6. The vaccine of claim 4 wherein the multiple antigenic peptide comprises the sequence VKNKRTFLSPWISNI (SEQ ID NO:2).
7. The vaccine of claim 4 , wherein the multiple antigenic peptide is octameric.
8. The vaccine of claim 4 , wherein the vaccine comprises an adjuvant.
9. A method to treat or immunize an animal against the cytotoxic effects of anthrax toxin, the method comprising administering to the animal the vaccine of claim 4 .
10. The method of claim 9 , wherein the multiple antigenic peptide in the vaccine comprises the sequence LKQKSSNSRKKRSTS (SEQ ID NO:1).
11. The method of claim 9 , wherein the multiple antigenic peptide in the vaccine comprises the sequence VKNKRTFLSPWISNI (SEQ ID NO:2).
12. A method of making a vaccine comprising formulating a multiple antigenic peptide of claim 1 in a dosage form for treating or immunizing an animal against the cytotoxic effects of anthrax toxin.
13. The method of claim 9 , wherein the animal is human.
14. The vaccine of claim 4 wherein the multiple antigenic peptide comprises between two and fourteen multiple peptide epitopes attached to the backbone.
15. The vaccine of claim 4 wherein the multiple antigenic peptide comprises between four and ten multiple peptide epitopes attached to the backbone.